Article

Effect of Beta Blockers on Exercise Capacity, Diastolic Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction: A Secondary Analysis of INDIE-HFpEF and RELAX

2024-09-23

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> The use of beta blockers in patients with heart failure with preserved ejection fraction (HFpEF) is common, with about 75% of patients in recent landmark clinical trials on beta blockers. Though the implementation of this medication class is routine, there is sparse data to support their use. Furthermore, beta blocker effects on exercise capacity, diastolic function, and quali...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9ef85458-196f-5dd3-b489-5824a3bff2e5
DOI: 10.1101/2024.09.20.24314104

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Effect of Beta Blockers on Exercise Capacity, Diastolic Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction: A Secondary Analysis of INDIE-HFpEF and RELAXDOI 10.1101/2024.09.20.24314104Read

Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials.Semantic proximity Read

Heart failure with non-reduced ejection fraction: Epidemiology, pathophysiology, phenotypes, diagnosis and treatment approaches.Semantic proximity Read

Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study.Semantic proximity Read

Diastolic heart failure: a myth.Semantic proximity Read

Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment.Semantic proximity Read

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Semantic proximity Read

Phenotype-guided approach for device-based therapies in heart failure.Semantic proximity Read

Cardiovascular drugs approved for heart failure with reduced ejection fraction and/or post-myocardial infarction exert consistent effects in both populations: A meta-analysis and meta-regression of randomized controlled trialsSemantic proximity Read

Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.Semantic proximity Read

Identification of distinct phenotypic clusters in heart failure with preserved ejection fractionSemantic proximity Read

Key Phenotypes of Heart Failure with Preserved Ejection Fraction: Pathophysiologic Mechanisms and Potential Treatment Strategies.Semantic proximity Read

Primary heart failure with preserved ejection fraction: The intertwined pathophysiology and treatment of some of the most relevant phenotypes.Semantic proximity Read